ART0380 for Cancer
(ARTIST Trial)
Trial Summary
What is the purpose of this trial?
This trial is testing ART0380, an oral cancer drug, in patients with advanced or hard-to-treat cancers. The drug targets a protein that helps cancer cells repair their DNA, making it harder for the cancer to survive. BO-1051 is a new anti-cancer drug that can effectively target a variety of cancer cell lines and inhibit tumor growth.
Eligibility Criteria
This trial is for adults with certain types of advanced endometrial or solid tumors predicted to respond to ATR inhibition. Participants must have stopped previous cancer treatments, have good organ function, use effective contraception if childbearing potential exists, and not be pregnant. They should also have a life expectancy over 12 weeks and a performance status allowing daily activity.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive ART0380 monotherapy in one of two dose regimens for a 21-day cycle
Follow-up
Participants are monitored for safety and effectiveness after treatment
Overall survival follow-up
Participants are monitored for overall survival
Treatment Details
Interventions
- ART0380
Find a Clinic Near You
Who Is Running the Clinical Trial?
Artios Pharma Ltd
Lead Sponsor